Katherine K. Matthay
Paediatric oncologist whose trials established transplant and 13-cis-retinoic acid for high-risk neuroblastoma.
Long-time chair of COG neuroblastoma studies. Led the CCG-3891 trial establishing myeloablative therapy and retinoic acid in high-risk neuroblastoma and pioneered 131I-MIBG therapy for relapsed disease.
Pages like this
not linked directly; found by shared links- TrialCOG ANBL1531
Shares 131I-MIBG (iobenguane I-131) therapy, Children's Oncology Group (COG), Neuroblastoma (paediatric).
- TechnologyMIBG imaging and 131I-MIBG therapy
Shares 131I-MIBG (iobenguane I-131) therapy, Neuroblastoma (paediatric), Radioligand therapy (beta emitters).
- IdeaMake paediatric combination studies part of every relevant adult cancer drug approval
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric).
- PersonThomas A. Hope
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Radioligand therapy (beta emitters).
- PersonEmily K. Bergsland
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Radioligand therapy (beta emitters).
- IdeaAn international consortium pooling the outcome of every treated child with cancer
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric).
- PersonRahul Aggarwal
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Radioligand therapy (beta emitters).
- IdeaCan MYC be drugged directly, and will patients tolerate it?
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Neuroblastoma (paediatric).